These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22239010)

  • 1. [Thrombotic complications following the treatment of multiple myeloma with new agents].
    Rupa-Matysek J; Gil L; Komarnicki M
    Pol Merkur Lekarski; 2011 Dec; 31(186):372-7. PubMed ID: 22239010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
    Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
    Shen Y; Zhou X; Wang Z; Yang G; Jiang Y; Sun C; Wang J; Tong Y; Guo H
    Leuk Res; 2011 Feb; 35(2):147-51. PubMed ID: 20832859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
    Teh BW; Worth LJ; Harrison SJ; Thursky KA; Slavin MA
    Support Care Cancer; 2015 Jul; 23(7):1901-6. PubMed ID: 25487843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
    Morita R; Hashino S; Shirai S; Fujita N; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
    Int J Hematol; 2008 Sep; 88(2):248-250. PubMed ID: 18636313
    [No Abstract]   [Full Text] [Related]  

  • 15. Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
    Guo HF; Su HL; Mao JJ; Sun C; Wang J; Zhou X
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):776-8. PubMed ID: 20979938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update of thrombosis in multiple myeloma.
    Leebeek FW
    Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on drug combinations for treatment of myeloma.
    Srikanth M; Davies FE; Morgan GJ
    Expert Opin Investig Drugs; 2008 Jan; 17(1):1-12. PubMed ID: 18095914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia].
    Nagamachi Y; Yamauchi N; Muramatsu H; Okamoto T; Inomata H; Nozawa E; Koyama R; Ihara K; Nishisato T; Yamada H; Yano T; Tanaka S; Ono K; Kikuchi S; Kato J
    Rinsho Ketsueki; 2013 May; 54(5):451-6. PubMed ID: 23727683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
    Rupa-Matysek J; Gil L; Wojtasińska E; Nowicki A; Dytfeld D; Kaźmierczak M; Komarnicki M
    Thromb Res; 2014 Aug; 134(2):404-11. PubMed ID: 24931724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.